Your session is about to expire
← Back to Search
Fecal microbiota transplant for Prostate Cancer
Study Summary
This trial will test whether combining immunotherapy with a fecal microbiota transplant will improve response rates in patients with metastatic cancer.
- Prostate Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 1 Patients • NCT03367910Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a cancerous growth that can be safely examined through a tissue sample, and you are willing to undergo the biopsy.You can participate in the trial even if you have received treatment with sipuleucel-T, radium-223, or abiraterone before.You have had radiation therapy within the past two weeks before starting the study treatment.You have recently taken medication for your condition and have not fully recovered from any side effects.You have a history of seizures, unless you have had a brain tumor, like meningioma, removed.You currently have an autoimmune disease or have symptoms that may suggest one.You have factors that increase your risk of getting sick.You have other medical conditions related to your digestive system.You are taking drugs that weaken your immune system.You have a mental illness or struggle with drug addiction that may make it difficult for you to follow the study's requirements.You have severe bone pain or other symptoms related to your disease that require immediate chemotherapy.You must stop taking all treatments for metastatic castration-resistant prostate cancer (mCRPC) except for enzalutamide and a GnRH agent for a certain amount of time before participating in the study.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Fecal microbiota transplant been investigated in other research?
"Currently, there are 1050 trials related to fecal microbiota transplant (FMT), 148 of which have advanced into Phase 3. Most FMT studies take place in Houston, Texas; however, 40730 locations host experiments for this particular treatment."
What is the capacity of this research project?
"Confirmed. Information on clinicaltrials.gov shows that the trial, which was inaugurated on October 30th 2019, is actively recruiting individuals for participation. A total of 32 people must be enrolled from a single location to fulfill the requirements of this study."
To what extent could Fecal microbiota transplant be harmful to individuals?
"In spite of the lack of evidence for its efficacy, Fecal microbiota transplant has some safety data backing it up. As such, our team at Power rated it a 2 on their scale from 1 to 3."
Can any additional candidates still join the research program?
"Clinicaltrials.gov indicates that this medical study is still recruiting patients, having been initially posted on October 30th 2019 and recently updated on June 21st 2022."
What conditions can Fecal microbiota transplant therapy treat?
"Fecal microbiota transplantation can be used to not only treat malignant neoplasms, but also systemically incurable melanomas, microsatellite instability-high conditions, and chemotherapy resistant cancers."
Share this study with friends
Copy Link
Messenger